Stryker Corporation (NYSE: SYK) is a Healthcare company in the Medical - Devices industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | S&P 500 | P/E | 34.84 | EPS (ttm) | 9.73 | Insider Own | 3.57% | Shs Outstand | 383.36M | Perf Week | 4.09% |
| Market Cap | 129.97B | Forward P/E | 20.22 | EPS next Y | 16.77 | Insider Trans | -2.36% | Shs Float | 347.76M | Perf Month | 3.64% |
| Enterprise Value | 141.52B | PEG | 1.28 | EPS next Q | 3.61 | Inst Own | 59.40% | Short Float | 2.02% | Perf Quarter | 15.23% |
| Income | 3.73B | P/S | 5.03 | EPS this Y | 55.43% | Inst Trans | - | Short Ratio | 2.59 | Perf Half Y | -6.45% |
| Sales | 25.84B | P/B | 5.42 | EPS next Y | 11.79% | ROA | 7.78% | Short Interest | 7.03M | Perf YTD | -3.54% |
| Book/sh | - | P/C | 23.53 | EPS next 5Y | 11.45% | ROE | 16.36% | 52W High | 404.66 -14.57% | Perf Year | -9.58% |
| Cash/sh | - | P/FCF | 27.64 | EPS past 3/5Y | 10.83% 14.87% | ROIC | 9.82% | 52W Low | 286.54 20.65% | Perf 3Y | 23.48% |
| Dividend Est. | 3.52 (1.02%) | EV/EBITDA | 22.63 | Sales past 3/5Y | 10.83% 11.84% | Gross Margin | 65.17% | Volatility | 2.71% 2.77% | Perf 5Y | 25.13% |
| Dividend TTM | 3.48 (1.01%) | EV/Sales | 5.48 | EPS Y/Y TTM | 24.36% | Oper. Margin | 22.03% | ATR (14) | 11.33 | Perf 10Y | 194.91% |
| Dividend Ex-Date | Jun 30, 2026 | Quick Ratio | 1.33 | Sales Y/Y TTM | 14.35% | Profit Margin | 14.43% | RSI (14) | 55.29 | Recom | 2.24 |
| Dividend Gr. 3/5Y | 6.25% 7.62% | Current Ratio | 2.16 | EPS Q/Q | 17.89% | SMA20 | 2.70% | Beta | 0.76 | Target Price | 382.61 |
| Payout | 35.32% | Debt/Eq | 0.62 | Sales Q/Q | 9.42% | SMA50 | 6.08% | Rel Volume | 0.66 | Prev Close | 339.03 |
| Employees | 56,000 | LT Debt/Eq | 0.68 | Earnings | Oct 29 | SMA200 | -0.96% | Avg Volume | 2.71M | Price | 345.70 |
| IPO Date | Mar 17, 1980 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 5.78% 0.15% | Net Debt/EBITDA | 1.85 | Volume | 1,802,372 | Change | 1.97% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Jul-31-26 | Reiterated | Raymond James | Outperform | $383 → $370 |
| Jul-31-26 | Reiterated | Wolfe Research | $375 | |
| Jul-31-26 | Reiterated | BTIG | Buy | $371 → $358 |
| Jul-31-26 | Reiterated | RBC Capital | Outperform | $435 → $420 |
| Jul-31-26 | Reiterated | Piper Sandler | Overweight | $420 → $390 |
| Jul-13-26 | Reiterated | BTIG | Buy | $379 → $371 |
| Jul-09-26 | Reiterated | Argus Research | Buy | $350 → $370 |
| Jul-09-26 | Upgrade | BMO Capital | Market Perform → Outperform | $369 |
| Jul-06-26 | Reiterated | Evercore ISI Group | Outperform | $355 → $350 |
| Jun-05-26 | Reiterated | Leerink Partners | Outperform | $285 → $407 |
Stryker Corporation functions as a prominent medical technology enterprise, with its operations structured across two main divisions. The Orthopaedics and Spine segment specializes in providing implants for joint replacement procedures (including hips and knees), as well as solutions for trauma and extremities surgeries. This division also furnishes a comprehensive suite of spinal implant products, such as cervical, thoracolumbar, and interbody systems, utilized in addressing spinal injuries, deformities, and degenerative conditions. The MedSurg and Neurotechnology division offers an extensive array of products, encompassing advanced surgical equipment, surgical navigation systems, endoscopic and communication tools, patient handling devices, emergency medical apparatus, and critical care disposable items. This segment also deals in reprocessed and remanufactured medical devices, catering to various medical specialties. Furthermore, its neurotechnology offerings include devices for minimally invasive endovascular techniques, instruments for brain and open skull-based surgical interventions, and orthobiologic and biosurgery products like synthetic bone grafts and vertebral augmentation solutions. It also provides specialized minimally invasive products for treating acute ischemic and hemorrhagic strokes, alongside craniomaxillofacial implants, which include cranial, maxillofacial, and chest wall devices, in addition to dural substitutes and sealants. Stryker distributes its diverse portfolio to medical professionals, hospitals, and other healthcare institutions in approximately 75 countries, leveraging its network of company-owned subsidiaries, regional branches, and independent dealers and distributors. Established in 1941, Stryker Corporation is headquartered in Kalamazoo, Michigan.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 25,837 | 25,116 | 22,595 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 9,000 | 9,051 | 8,615 | — | — | — | — | — | — | |
| Gross Profit | 16,837 | 16,065 | 13,980 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 8,782 | 8,651 | 7,505 | — | — | — | — | — | — | |
| Research and Development | 1,658 | 1,582 | 1,414 | — | — | — | — | — | — | |
| Other Operating Expense | 706 | 943 | 0 | — | — | — | — | — | — | |
| Operating Income | 5,691 | 4,889 | 5,061 | — | — | — | — | — | — | |
| Interest Expense | 686 | 607 | 396 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 143 | 232 | -1,173 | — | — | — | — | — | — | |
| Net Income Before Taxes | 5,148 | 4,514 | 3,492 | — | — | — | — | — | — | |
| Income Taxes | 1,419 | 1,268 | 499 | — | — | — | — | — | — | |
| Consolidated Net Income | 3,729 | 3,246 | 2,993 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | 3,729 | 3,246 | 2,993 | — | — | — | — | — | — | |
| Net Income | 3,729 | 3,246 | 2,993 | — | — | — | — | — | — | |
| EPS (Recurring) | 9.73 | 8.49 | 7.86 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 9.73 | 8.49 | 7.86 | — | — | — | — | — | — | |
| EPS (Diluted) | 9.65 | 8.40 | 7.76 | — | — | — | — | — | — | |
| EBITDA | 6,255 | 6,314 | 4,938 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 35.82 | 41.84 | 46.40 | — | — | — | — | — | — | |
| Price To Sales Ratio | 5.14 | 5.35 | 6.07 | — | — | — | — | — | — | |
| Gross Margin | 65.17 | 63.96 | 61.87 | — | — | — | — | — | — | |
| Operating Margin | 22.03 | 19.47 | 22.40 | — | — | — | — | — | — | |
| Net Margin | 14.43 | 12.92 | 13.25 | — | — | — | — | — | — | |
| Shares Outstanding | 384 | 382 | 381 | — | — | — | — | — | — | |
| Market Capitalization | 132,751 | 134,262 | 137,179 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Fletcher Robert S | VP, Chief Legal Officer | May 28 '26 | Sale | 306.87 | 4,544 | 1,394,410 | 10,582 | May 29 |
| STRYKER RONDA E | Director | May 26 '26 | Sale | 312.23 | 310,000 | 96,792,669 | 1,924,880 | May 28 |
| Fink M Kathryn | VP, Chief HR Officer | May 11 '26 | Sale | 283.69 | 8,720 | 2,473,756 | 177 | May 12 |
| Fink M Kathryn | VP, Chief HR Officer | May 08 '26 | Option Exercise | 167.98 | 21,582 | 3,625,388 | 34,719 | May 12 |
| Stiles Spencer S | President and COO | Mar 21 '26 | Option Exercise | 0.00 | 430 | 0 | 84,324 | Mar 24 |
| Pierce James Andrew | Group President | Mar 21 '26 | Option Exercise | 0.00 | 430 | 0 | 88,676 | Mar 24 |
| Menon Viju | Group President | Mar 21 '26 | Option Exercise | 0.00 | 269 | 0 | 22,100 | Mar 24 |
| Lobo Kevin | Chair and CEO | Mar 21 '26 | Option Exercise | 0.00 | 1,452 | 0 | 248,723 | Mar 24 |
| Fletcher Robert S | VP, Chief Legal Officer | Mar 21 '26 | Option Exercise | 0.00 | 225 | 0 | 18,510 | Mar 24 |
| Fink M Kathryn | VP, Chief HR Officer | Mar 21 '26 | Option Exercise | 0.00 | 150 | 0 | 18,701 | Mar 24 |
| Lobo Kevin | Chair and CEO | Feb 06 '26 | Option Exercise | 96.64 | 206,955 | 20,000,131 | 329,350 | Feb 06 |
| STRYKER RONDA E | Director | Feb 05 '26 | Sale | 363.95 | 250,000 | 90,988,528 | 2,207,331 | Feb 06 |
| STRYKER RONDA E | Director | Feb 04 '26 | Sale | 362.92 | 250,000 | 90,730,741 | 2,457,331 | Feb 06 |
| Stiles Spencer S | President and COO | Feb 03 '26 | Option Exercise | 96.64 | 13,840 | 1,337,498 | 76,674 | Feb 04 |
| Pierce James Andrew | Group President | Feb 02 '26 | Option Exercise | 96.64 | 13,840 | 1,337,498 | 79,470 | Feb 03 |